DOCSLIB.ORG

Ubiquitin E3 Ligases in Lung Disease by Travis Bradley Lear BA, Saint

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ubiquitin E3 Ligases in Lung Disease by Travis Bradley Lear BA, Saint Title Page Ubiquitin E3 Ligases in Lung Disease by Travis Bradley Lear BA, Saint Mary’s College of Maryland, 2012 Submitted to the Graduate Faculty of the Department of Environmental and Occupational Health Graduate School of Public Health in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2020 Committee Page UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH This dissertation was presented by Travis Bradley Lear It was defended on March 6, 2020 and approved by Aaron Barchowsky, PhD, Professor, Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh Bruce R. Pitt, PhD, Professor, Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh Toren Finkel, MD, PhD, Professor of Medicine, Department of Medicine, School of Medicine, University of Pittsburgh Dissertation Advisor: Bill B. Chen, PhD, Associate Professor of Medicine, Department of Medicine, School of Medicine, University of Pittsburgh ii Copyright © by Travis Bradley Lear 2020 iii Abstract Bill B. Chen, PhD Ubiquitin E3 Ligases in Lung Disease Travis Bradley Lear, PhD University of Pittsburgh, 2020 Abstract Diseases of the lung form the one of the largest causes of death globally. Inflammatory diseases such as Acute Respiratory Distress Syndrome, and fibrosis such as interstitial lung disease, in particular have high mortality rates with limited therapy. Thus, there is an unmet public health need for new avenues of intervention. Inflammatory, fibrotic, and nutrient lung diseases are driven by cellular signaling pathways, leading to pathological cell responses. Effector lung cells naturally dampen these deleterious signaling pathways; dysfunction of these dampening mechanisms play causal roles in lung disease, notably through excessive destruction of critical signal transduction proteins. Modulation of signal transduction protein degradation may have therapeutic effect by controlling deleterious signaling. The ubiquitin-proteasome system is the major cellular mechanism controlling protein degradation. Ubiquitin E3 ligase proteins are a critical part of ubiquitination, specifically targeting substrates for degradation. Research shows the importance of protein degradation in lung disease, however the potential to identify and inhibit specific E3-ligase-substrate interactions remains unexplored. Through both candidate-based and unbiased high-throughput screening techniques, we probed the importance of E3 ligases in lung disease through their targeted degradation of signal transduction proteins, and the therapeutic potential of E3 ligase inhibition. We investigated three aspects of lung disease – 1) inflammation and innate immunity, 2) fibrosis and interstitial lung disease, and 3) regulation of nutrient sensing mechanisms. Here we report multiple E3 ligase-substrate axes, including those associated with iv fibrosis: FIEL1-PIAS4; KLHL42-PPP2R5e, with innate immunity: PPP1R11-TLR2, RNF113A- CXCR4, KIAA0317-SOCS2, RNFT2-IL3Ra, and with nutrient sensing: RNF186-SESN2. We observed that E3 ligases potently control inflammatory signaling through control of cytokine receptors and signal modulators during acute inflammation and bacterial infection. We uncovered that E3 ligases are significantly associated with fibrotic signaling in interstitial lung fibrosis, and can be targeted by small molecules. Finally, we detected new mechanisms of nutrient sensor control leading to manipulation of anabolism. These results show the criticality of ubiquitin e3 ligases in the biology of lung inflammation, fibrosis, and nutrient sensing. Further, these studies validate ubiquitin E3 ligases as potential targets for therapeutic intervention to provide new tools to combat lung diseases. v Table of Contents Preface ......................................................................................................................................... xxi 1.0 Introduction ............................................................................................................................. 1 1.1 Diseases of Lung ............................................................................................................. 1 1.1.1 Global Public Health Significance of Lung Disease ..........................................2 1.1.2 Fibrosis in the Lung .............................................................................................3 Idiopathic Pulmonary Fibrosis ............................................................... 3 Determinants of IPF Pathology .............................................................. 4 Therapeutic Options for IPF .................................................................. 4 1.1.3 Inflammation in the Lung ...................................................................................7 1.1.4 Nutrient Sensing in the Lung ..............................................................................9 1.2 Protein Degradation ..................................................................................................... 10 1.2.1 Protein Lifespan .................................................................................................10 1.2.2 The Ubiquitin Proteasome System ...................................................................11 1.2.3 Ubiquitin E3 Ligases ..........................................................................................12 Ubiquitin E3 Ligases in disease ............................................................ 14 1.3 Specific Aims ................................................................................................................. 16 2.0 Ubiquitination in Fibrosis .................................................................................................... 18 2.1 Ubiquitin E3 Ligase FIEL1 Regulates Fibrotic Lung Injury through SUMO-E3 Ligase PIAS4 ....................................................................................................................... 18 2.1.1 Study Overview ..................................................................................................18 2.1.2 Introduction ........................................................................................................19 vi PIAS proteins and SMAD signaling ..................................................... 20 2.1.3 FIEL1-PIAS4 pathway in pulmonary fibrosis ................................................21 2.1.4 FIEL1 promotes TGF signaling ......................................................................25 2.1.5 PIAS4 phosphorylation by PKCζ is required for FIEL1 binding .................27 2.1.6 GSK3 phosphorylation of FIEL1 is required for PIAS4 targeting .............29 2.1.7 Gene transfer of FIEL1 exacerbates bleomycin induced lung injury in vivo .......................................................................................................................................33 2.1.8 FIEL1 knockdown ameliorates bleomycin-induced lung injury in vivo .......35 2.1.9 Anti-fibrotic activity of a FIEL1 small molecule inhibitor.............................37 In vitro .................................................................................................... 37 In vivo ..................................................................................................... 38 2.1.10 Discussion ..........................................................................................................42 2.1.11 Acknowledgements ...........................................................................................45 2.1.12 Materials and Methods ....................................................................................45 Materials ............................................................................................... 45 Human Samples ................................................................................... 46 Cell culture ........................................................................................... 46 In vitro protein binding assays ........................................................... 47 In vitro peptide binding assays ........................................................... 47 In vitro drug binding assays ............................................................... 47 In vitro ubiquitin conjugation assays ................................................. 48 In vitro kinase assays ........................................................................... 48 Hydroxyproline Assay ......................................................................... 48 vii SMAD reporter assay ........................................................................ 49 Immunostaining ................................................................................. 49 Molecular docking studies and compound design .......................... 49 BC-1485 synthesis .............................................................................. 50 RT–qPCR, cloning, and mutagenesis............................................... 50 Lentivirus construction ..................................................................... 51 Animal studies .................................................................................... 51 Tissue Staining ................................................................................... 52 Statistical Analysis ............................................................................. 52 2.2 Kelch-like Protein 42 is a Pro-Fibrotic Ubiquitin E3 Ligase in Systemic
Load more

Recommended publications
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Novel Mutation and Three Other Sequence Variants Segregating with Phenotype at Keratoconus 13Q32 Susceptibility Locus
    European Journal of Human Genetics (2012) 20, 389–397 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Novel mutation and three other sequence variants segregating with phenotype at keratoconus 13q32 susceptibility locus Marta Czugala1,6, Justyna A Karolak1,6, Dorota M Nowak1, Piotr Polakowski2, Jose Pitarque3, Andrea Molinari3, Malgorzata Rydzanicz1, Bassem A Bejjani4, Beatrice YJT Yue5, Jacek P Szaflik2 and Marzena Gajecka*,1 Keratoconus (KTCN), a non-inflammatory corneal disorder characterized by stromal thinning, represents a major cause of corneal transplantations. Genetic and environmental factors have a role in the etiology of this complex disease. Previously reported linkage analysis revealed that chromosomal region 13q32 is likely to contain causative gene(s) for familial KTCN. Consequently, we have chosen eight positional candidate genes in this region: MBNL1, IPO5, FARP1, RNF113B, STK24, DOCK9, ZIC5 and ZIC2, and sequenced all of them in 51 individuals from Ecuadorian KTCN families and 105 matching controls. The mutation screening identified one mutation and three sequence variants showing 100% segregation under a dominant model with KTCN phenotype in one large Ecuadorian family. These substitutions were found in three different genes: c.2262A4C (p.Gln754His) and c.720+43A4GinDOCK9; c.2377-132A4CinIPO5 and c.1053+29G4CinSTK24. PolyPhen analyses predicted that c.2262A4C (Gln754His) is possibly damaging for the protein function and structure. Our results suggest that c.2262A4C (p.Gln754His)
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Small-Molecule Inhibitors of Protein Acetylation and Deacetylation
    Downloaded from rnajournal.cshlp.org on March 23, 2009 - Published by Cold Spring Harbor Laboratory Press Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation Andreas N. Kuhn, Maria A. van Santen, Andreas Schwienhorst, et al. RNA 2009 15: 153-175 originally published online November 24, 2008 Access the most recent version at doi:10.1261/rna.1332609 References This article cites 65 articles, 36 of which can be accessed free at: http://rnajournal.cshlp.org/content/15/1/153.full.html#ref-list-1 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article or click here To subscribe to RNA go to: http://rnajournal.cshlp.org/subscriptions Copyright © 2009 RNA Society JOBNAME: RNA 15#1 2009 PAGE: 1 OUTPUT: Tuesday December 9 15:25:03 2008 csh/RNA/175400/rna13326 Downloaded from rnajournal.cshlp.org on March 23, 2009 - Published by Cold Spring Harbor Laboratory Press Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation ANDREAS N. KUHN,1 MARIA A. VAN SANTEN,1 ANDREAS SCHWIENHORST,2 HENNING URLAUB,3 and REINHARD LU¨ HRMANN1 1Department of Cellular Biochemistry, Max Planck Institute for Biophysical Chemistry, D-37077 Go¨ttingen, Germany 2Department of Molecular Genetics and Preparative Molecular Biology, Institute for Microbiology and Genetics, D-37077 Go¨ttingen, Germany 3Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, D-37077 Go¨ttingen, Germany ABSTRACT The removal of intervening sequences from a primary RNA transcript is catalyzed by the spliceosome, a large complex consisting of five small nuclear (sn) RNAs and more than 150 proteins.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • A Family of Signal-Responsive E3 Ubiquitin Ligases Mediating TLR Signaling and T-Cell Tolerance
    Cellular & Molecular Immunology (2012) 9, 113–122 ß 2012 CSI and USTC. All rights reserved 1672-7681/12 $32.00 www.nature.com/cmi REVIEW Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance Wei Jin1, Mikyoung Chang2 and Shao-Cong Sun2 E3 ubiquitin ligases play a crucial role in regulating immune receptor signaling and modulating immune homeostasis and activation. One emerging family of such E3s is the Pelle-interacting (Peli) proteins, characterized by the presence of a cryptic forkhead-associated domain involved in substrate binding and an atypical RING domain mediating formation of both lysine (K) 63- and K48-linked polyubiquitin chains. A well-recognized function of Peli family members is participation in the signal transduction mediated by Toll-like receptors (TLRs) and IL-1 receptor. Recent gene targeting studies have provided important insights into the in vivo functions of Peli1 in the regulation of TLR signaling and inflammation. These studies have also extended the biological functions of Peli1 to the regulation of T-cell tolerance. Consistent with its immunoregulatory functions, Peli1 responds to different immune stimuli for its gene expression and catalytic activation. In this review, we discuss the recent progress, as well as the historical perspectives in the regulation and biological functions of Peli. Cellular & Molecular Immunology (2012) 9, 113–122; doi:10.1038/cmi.2011.60; published online 6 February 2012 Keywords: Peli; Pellino; ubiquitination; NF-kB; TLR; T-cell tolerance
    [Show full text]
  • Cotranscriptional Splicing Efficiency Differs Dramatically Between Drosophila and Mouse
    Downloaded from rnajournal.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press Cotranscriptional splicing efficiency differs dramatically between Drosophila and mouse YEVGENIA L. KHODOR,1 JEROME S. MENET, MICHAEL TOLAN, and MICHAEL ROSBASH2 Howard Hughes Medical Institute and National Center for Behavioral Genomics, Department of Biology, Brandeis University, Waltham, Massachusetts 02454, USA ABSTRACT Spliceosome assembly and/or splicing of a nascent transcript may be crucial for proper isoform expression and gene regulation in higher eukaryotes. We recently showed that cotranscriptional splicing occurs efficiently in Drosophila, but there are not comparable genome-wide nascent splicing data from mammals. To provide this comparison, we analyze a recently generated, high-throughput sequencing data set of mouse liver nascent RNA, originally studied for circadian transcriptional regulation. Cotranscriptional splicing is approximately twofold less efficient in mouse liver than in Drosophila, i.e., nascent intron levels relative to exon levels are ~0.55 in mouse versus 0.25 in the fly. An additional difference between species is that only mouse cotranscriptional splicing is optimal when 59-exon length is between 50 and 500 bp, and intron length does not correlate with splicing efficiency, consistent with exon definition. A similar analysis of intron and exon length dependence in the fly is more consistent with intron definition. Contrasted with these differences are many similarities between the two systems: Alternatively annotated introns are less efficiently spliced cotranscriptionally than constitutive introns, and introns of single-intron genes are less efficiently spliced than introns from multi-intron genes. The most striking common feature is intron position: Cotranscrip- tional splicing is much more efficient when introns are far from the 39 ends of their genes.
    [Show full text]
  • Mrna Editing, Processing and Quality Control in Caenorhabditis Elegans
    | WORMBOOK mRNA Editing, Processing and Quality Control in Caenorhabditis elegans Joshua A. Arribere,*,1 Hidehito Kuroyanagi,†,1 and Heather A. Hundley‡,1 *Department of MCD Biology, UC Santa Cruz, California 95064, †Laboratory of Gene Expression, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 113-8510, Japan, and ‡Medical Sciences Program, Indiana University School of Medicine-Bloomington, Indiana 47405 ABSTRACT While DNA serves as the blueprint of life, the distinct functions of each cell are determined by the dynamic expression of genes from the static genome. The amount and specific sequences of RNAs expressed in a given cell involves a number of regulated processes including RNA synthesis (transcription), processing, splicing, modification, polyadenylation, stability, translation, and degradation. As errors during mRNA production can create gene products that are deleterious to the organism, quality control mechanisms exist to survey and remove errors in mRNA expression and processing. Here, we will provide an overview of mRNA processing and quality control mechanisms that occur in Caenorhabditis elegans, with a focus on those that occur on protein-coding genes after transcription initiation. In addition, we will describe the genetic and technical approaches that have allowed studies in C. elegans to reveal important mechanistic insight into these processes. KEYWORDS Caenorhabditis elegans; splicing; RNA editing; RNA modification; polyadenylation; quality control; WormBook TABLE OF CONTENTS Abstract 531 RNA Editing and Modification 533 Adenosine-to-inosine RNA editing 533 The C. elegans A-to-I editing machinery 534 RNA editing in space and time 535 ADARs regulate the levels and fates of endogenous dsRNA 537 Are other modifications present in C.
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]
  • Supplementary Table S1. List of Differentially Expressed
    Supplementary table S1. List of differentially expressed transcripts (FDR adjusted p‐value < 0.05 and −1.4 ≤ FC ≥1.4). 1 ID Symbol Entrez Gene Name Adj. p‐Value Log2 FC 214895_s_at ADAM10 ADAM metallopeptidase domain 10 3,11E‐05 −1,400 205997_at ADAM28 ADAM metallopeptidase domain 28 6,57E‐05 −1,400 220606_s_at ADPRM ADP‐ribose/CDP‐alcohol diphosphatase, manganese dependent 6,50E‐06 −1,430 217410_at AGRN agrin 2,34E‐10 1,420 212980_at AHSA2P activator of HSP90 ATPase homolog 2, pseudogene 6,44E‐06 −1,920 219672_at AHSP alpha hemoglobin stabilizing protein 7,27E‐05 2,330 aminoacyl tRNA synthetase complex interacting multifunctional 202541_at AIMP1 4,91E‐06 −1,830 protein 1 210269_s_at AKAP17A A‐kinase anchoring protein 17A 2,64E‐10 −1,560 211560_s_at ALAS2 5ʹ‐aminolevulinate synthase 2 4,28E‐06 3,560 212224_at ALDH1A1 aldehyde dehydrogenase 1 family member A1 8,93E‐04 −1,400 205583_s_at ALG13 ALG13 UDP‐N‐acetylglucosaminyltransferase subunit 9,50E‐07 −1,430 207206_s_at ALOX12 arachidonate 12‐lipoxygenase, 12S type 4,76E‐05 1,630 AMY1C (includes 208498_s_at amylase alpha 1C 3,83E‐05 −1,700 others) 201043_s_at ANP32A acidic nuclear phosphoprotein 32 family member A 5,61E‐09 −1,760 202888_s_at ANPEP alanyl aminopeptidase, membrane 7,40E‐04 −1,600 221013_s_at APOL2 apolipoprotein L2 6,57E‐11 1,600 219094_at ARMC8 armadillo repeat containing 8 3,47E‐08 −1,710 207798_s_at ATXN2L ataxin 2 like 2,16E‐07 −1,410 215990_s_at BCL6 BCL6 transcription repressor 1,74E‐07 −1,700 200776_s_at BZW1 basic leucine zipper and W2 domains 1 1,09E‐06 −1,570 222309_at
    [Show full text]
  • Stalling of Spliceosome Assembly at Distinct Stages by Small-Molecule Inhibitors of Protein Acetylation and Deacetylation
    JOBNAME: RNA 15#1 2009 PAGE: 1 OUTPUT: Tuesday December 9 15:25:03 2008 csh/RNA/175400/rna13326 Downloaded from rnajournal.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press Stalling of spliceosome assembly at distinct stages by small-molecule inhibitors of protein acetylation and deacetylation ANDREAS N. KUHN,1 MARIA A. VAN SANTEN,1 ANDREAS SCHWIENHORST,2 HENNING URLAUB,3 and REINHARD LU¨ HRMANN1 1Department of Cellular Biochemistry, Max Planck Institute for Biophysical Chemistry, D-37077 Go¨ttingen, Germany 2Department of Molecular Genetics and Preparative Molecular Biology, Institute for Microbiology and Genetics, D-37077 Go¨ttingen, Germany 3Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, D-37077 Go¨ttingen, Germany ABSTRACT The removal of intervening sequences from a primary RNA transcript is catalyzed by the spliceosome, a large complex consisting of five small nuclear (sn) RNAs and more than 150 proteins. At the start of the splicing cycle, the spliceosome assembles anew onto each pre-mRNA intron in an ordered process. Here, we show that several small-molecule inhibitors of protein acetylation/deacetylation block the splicing cycle: by testing a small number of bioactive compounds, we found that three small-molecule inhibitors of histone acetyltransferases (HATs), as well as three small-molecule inhibitors of histone deacetylases (HDACs), block pre-mRNA splicing in vitro. By purifying and characterizing the stalled spliceosomes, we found that the splicing cycle is blocked at distinct stages by different inhibitors: two inhibitors allow only the formation of A-like spliceosomes (as determined by the size of the stalled complexes and their snRNA composition), while the other compounds inhibit activation for catalysis after incorporation of all U snRNPs into the spliceosome.
    [Show full text]
  • 2012/037456 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date - 22 March 2012 (22.03.2012) 2012/037456 Al (51) International Patent Classification: (74) Agents: RESNICK, David, S. et al; Nixon Peabody CI2Q 1/68 (2006.01) LLP, 100 Summer Street, Boston, MA 021 10 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US201 1/05 193 1 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 16 September 201 1 (16.09.201 1) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, 61/384,030 17 September 2010 (17.09.2010) US RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/429,965 5 January 201 1 (05.01 .201 1) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): PRESI¬ DENT AND FELLOWS OF HARVARD COLLEGE (84) Designated States (unless otherwise indicated, for every [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
    [Show full text]